JP2011512163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011512163A5 JP2011512163A5 JP2010547822A JP2010547822A JP2011512163A5 JP 2011512163 A5 JP2011512163 A5 JP 2011512163A5 JP 2010547822 A JP2010547822 A JP 2010547822A JP 2010547822 A JP2010547822 A JP 2010547822A JP 2011512163 A5 JP2011512163 A5 JP 2011512163A5
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- autism
- cnv
- snp
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000349 chromosome Anatomy 0.000 claims 59
- 238000000034 method Methods 0.000 claims 31
- 206010003805 Autism Diseases 0.000 claims 26
- 208000020706 Autistic disease Diseases 0.000 claims 26
- 102000039446 nucleic acids Human genes 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 19
- 150000007523 nucleic acids Chemical class 0.000 claims 19
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 12
- 208000029560 autism spectrum disease Diseases 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 230000007372 neural signaling Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 102000000905 Cadherin Human genes 0.000 claims 1
- 108050007957 Cadherin Proteins 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3013608P | 2008-02-20 | 2008-02-20 | |
| US61/030,136 | 2008-02-20 | ||
| US10716308P | 2008-10-21 | 2008-10-21 | |
| US61/107,163 | 2008-10-21 | ||
| PCT/US2009/034784 WO2009105718A1 (en) | 2008-02-20 | 2009-02-20 | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011512163A JP2011512163A (ja) | 2011-04-21 |
| JP2011512163A5 true JP2011512163A5 (https=) | 2012-04-05 |
| JP6078211B2 JP6078211B2 (ja) | 2017-02-15 |
Family
ID=40985948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547822A Expired - Fee Related JP6078211B2 (ja) | 2008-02-20 | 2009-02-20 | 自閉症および自閉症の表現型に関連する遺伝子変化ならびに自閉症の診断および治療に対するその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9783851B2 (https=) |
| EP (1) | EP2257644B1 (https=) |
| JP (1) | JP6078211B2 (https=) |
| AU (1) | AU2009217278B2 (https=) |
| CA (1) | CA2716375C (https=) |
| WO (1) | WO2009105718A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| JP5881420B2 (ja) * | 2008-11-12 | 2016-03-09 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 自閉症関連遺伝子マーカー |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| US8772242B2 (en) | 2009-10-26 | 2014-07-08 | Thomas Julius Borody | Therapy for enteric infections |
| CA2807505A1 (en) * | 2010-08-24 | 2012-03-01 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| CA2834286A1 (en) * | 2011-04-27 | 2012-11-01 | Northwestern University | Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders |
| WO2012173809A2 (en) * | 2011-06-02 | 2012-12-20 | Ehli Erik | Method of identifying de novo copy number variants (cnv) using mz twins discordant for attention problems/disorders |
| CA2798906A1 (en) * | 2011-12-22 | 2013-06-22 | Mohammed Uddin | Genome-wide detection of genomic rearrangements and use of genomic rearrangements to diagnose genetic disease |
| US20130210657A1 (en) * | 2012-01-25 | 2013-08-15 | The Hospital For Sick Children | Method of Determining Risk of Autism Spectrum Disorder |
| AU2013230045A1 (en) * | 2012-03-05 | 2014-09-11 | Berg Llc | Compositions and methods for diagnosis and treatment of pervasive developmental disorder |
| JP2015510756A (ja) * | 2012-03-09 | 2015-04-13 | アンテグラージェン | 自閉症のリスクを評価するため遺伝子型決定テスト |
| WO2013139861A1 (en) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| MX357392B (es) | 2012-04-02 | 2018-07-06 | Berg Llc | Ensayos basados en interrogatorios celulares y uso de los mismos. |
| WO2014012144A1 (en) * | 2012-07-20 | 2014-01-23 | The University Of Melbourne | Method of diagnosing or prognosing a neurological disorder |
| JP2016506962A (ja) | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| PE20151416A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| EP2951186B1 (en) | 2013-01-29 | 2018-07-25 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| CN114203296B (zh) | 2014-09-11 | 2025-10-17 | 布普格生物制药公司 | 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型 |
| WO2016057810A1 (en) * | 2014-10-08 | 2016-04-14 | The Broad Institute, Inc. | Markers for assessing risk of developing or having obsessive compulsive disorder |
| WO2016109449A1 (en) * | 2014-12-29 | 2016-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of diagnosing autism spectrum disorders |
| PL4023222T3 (pl) | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| PE20190174A1 (es) | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102465758B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| AU2017306158B2 (en) | 2016-08-01 | 2021-10-14 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003052086A1 (en) * | 2001-12-14 | 2003-06-26 | President And Fellows Of Harvard College | Immune related neuronal receptors and therapeutic uses thereof |
| EP1554403A1 (en) * | 2002-10-10 | 2005-07-20 | K.U. Leuven Research and Development | Autism gene |
-
2009
- 2009-02-20 WO PCT/US2009/034784 patent/WO2009105718A1/en not_active Ceased
- 2009-02-20 CA CA2716375A patent/CA2716375C/en active Active
- 2009-02-20 EP EP09713119.7A patent/EP2257644B1/en active Active
- 2009-02-20 AU AU2009217278A patent/AU2009217278B2/en not_active Ceased
- 2009-02-20 US US12/918,508 patent/US9783851B2/en active Active
- 2009-02-20 JP JP2010547822A patent/JP6078211B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-09 US US15/727,868 patent/US20180148786A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512163A5 (https=) | ||
| Liang et al. | Cell-type-specific effects of genetic variation on chromatin accessibility during human neuronal differentiation | |
| Volpi et al. | Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia | |
| JP2010528590A5 (https=) | ||
| EP3977996A1 (en) | Methods of diagnosing and treating tourette syndrome | |
| JP2012503985A5 (https=) | ||
| CA2881027C (en) | Prognosis biomarkers in cartilage disorders | |
| JP2014533949A5 (https=) | ||
| CN104736723B (zh) | 用于预测对fgf‑18化合物的响应性的遗传标记 | |
| US20190055603A1 (en) | System and method for processing genotype information relating to drug metabolism | |
| US20210404002A1 (en) | Quantitative Algorithm for Endometriosis | |
| JP2013507127A5 (https=) | ||
| US20190233902A1 (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| JP2016540729A (ja) | 酢酸グラチラマーへの応答を予測する遺伝子マーカー | |
| Quast et al. | Rare variants in TMEM132D in a case–control sample for panic disorder | |
| EP2430184A2 (en) | Sca risk stratification by predicting patient response to anti-arrhythmics | |
| Fiorentino et al. | Genetic variation in the miR‐708 gene and its binding targets in bipolar disorder | |
| Pisanu et al. | Convergent analysis of genome‐wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder | |
| JP2011523552A5 (https=) | ||
| Polakkattil et al. | Methylome-wide and meQTL analysis helps to distinguish treatment response from non-response and pathogenesis markers in schizophrenia | |
| WO2010111080A2 (en) | Optimized treatment of schizophrenia | |
| US20160076104A1 (en) | Methods and compositions for assessment of pulmonary function and disorders | |
| CA3174572A1 (en) | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | |
| JP2010525788A (ja) | 心臓血管機能及び障害の評価のための方法及び組成物 | |
| JP5787337B2 (ja) | Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット |